康柏西普与雷珠单抗治疗早产儿视网膜病变的多中心随机对照试验临床结局比较
结果显示两组复发率无显著统计学差异(16.67% vs 23.34%,χ2=0.83,p=0.36),除3眼并发性白内障外无其他并发症,表明两种治疗均有效。
要点
- IVC组10眼(16.67%)与IVR组14眼(23.34%)复发,差异无统计学意义(χ2=0.83,p=0.36)。
- 两组首次注射时矫正胎龄(PMA)分别为(34.60±3.47)周与(35.14±1.76)周,无显著差异。
- 除3眼并发性白内障外,两组均无其他并发症。
核心结论
- 玻璃体腔注射康柏西普与雷珠单抗治疗早产儿视网膜病变均有效,康柏西普是治疗ROP的新选择。
研究设计与样本
- 多中心前瞻性随机对照试验,2017年5月至2019年2月纳入经双目间接检眼镜和RetCam3诊断为急进性后极部ROP、I区或后部II区需治疗ROP的患儿,随机接受0.25 mg康柏西普或0.25 mg雷珠单抗玻璃体腔注射,随访6个月。
主要发现
- IVC组30例(60眼)与IVR组30例(60眼)完成治疗,复发率分别为16.67%(10眼)和23.34%(14眼),差异无统计学意义(χ2=0.83,p=0.36)。
- 复发患儿中,IVC组与IVR组第二次治疗时平均PMA分别为(43.31±3.85)周和(43.43±3.89)周,两次治疗间隔分别为(8.71±6.62)周和(8.29±2.56)周,均无显著统计学差异。
- 眼底荧光血管造影(FFA)显示复发患儿眼存在荧光渗漏。
- 除3眼并发性白内障外,两组均无其他并发症。
关键数值与推荐
- 复发眼在72小时内接受激光或再次玻璃体腔注射治疗。
临床怎么用
- 对于急进性后极部ROP、I区或后部II区需治疗ROP,可考虑玻璃体腔注射康柏西普0.25 mg或雷珠单抗0.25 mg,两者复发率与并发症相似。
- 治疗后6个月内需密切随访,复发眼应及时行激光或再次注射治疗。
局限性
- 随访期仅6个月,样本量较小(每组30例),远期疗效与安全性需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the recurrence rate and surgical complications of retinopathy of prematurity (ROP) between patients treated with intravitreal injection of conbercept (IVC) and intravitreal injection of ranibizumab (IVR) within 6 months. METHODS: A multicentral prospective, randomised controlled trial was applied from May 2017 to February 2019 for the infants diagnosed as aggressive posterior-ROP, zone I or posterior zone II treatment-requiring ROP by binocular indirect ophthalmoscope and RetCam3. These infants were assigned to randomly receive either intravitreal injection of 0.25 mg conbercept or 0.25 mg ranibizumab. The recurrence rate, fundus fluorescence angiography (FFA) and surgical complications were examined during the follow-up period of 6 months. Recurrent eyes were retreated by laser or another intravitreal injection within the 72 hours. RESULTS: A total of 30 infant patients (60 eyes) underwent IVC and 30 patients (60 eyes) underwent IVR. A total of 10 eyes (16.67%) in the IVC group and 14 eyes (23.34%) in the IVR group developed recurrence. There was no significant statistical difference in the recurrence rate between the two groups (χ2=0.83, p=0.36). The postmenstrual age (PMA) at first injection was (34.60±3.47) weeks in IVC and (35.14±1.76) in IVR group. In recurrent cases, the mean PMA at second treatment were (43.31±3.85) and (43.43±3.89) weeks in the IVC and IVR group, respectively. The period between two treatments was (8.71±6.62) for the IVC and (8.29±2.56) weeks for the IVR group. All these results showed no significant statistical difference between these two groups. The fluorescein leakage were observed in the eyes of recurrent infants by FFA. There were no other complications in the two groups except for complicated cataract in three eyes. CONCLUSION: Both IVC and IVR are effective therapies for the treatment of ROP. Conbercept is a new option for treating ROP.
引用
- Wu Z, Zhao J, Lam W, et al. Comparison of clinical outcomes of conbercept versus ranibizumab treatment for retinopathy of prematurity: a multicentral prospective randomised controlled trial. Br J Ophthalmol. 2021. PMID: 33637618. doi:10.1136/bjophthalmol-2020-318026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。